Edwards Lifesciences Financial Ratios

Edwards Lifesciences Corporation -- USA Stock  

USD 137.09  1.47  1.06%

We urge you to utilize Edwards Lifesciences fundamental analysis to see if markets are presently mispricing the company. In plain English you can exercise it to find out if Edwards Lifesciences is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. . We found thirty-five available fundamental indicators for Edwards Lifesciences Corporation which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Edwards Lifesciences fundamentals including its EBITDA, Earnings Per Share, Z Score, as well as the relationship between Debt to Equity and Total Asset . Given that Edwards Lifesciences has Price to Earning of 50.77 times, we urge you verify Edwards Lifesciences Corporation prevailing market performance to make sure the company can sustain itself down the road.Use Edwards Lifesciences to protect against small markets fluctuations. The stock experiences somewhat bearish sentiment, but market may correct it shortly. Check odds of Edwards Lifesciences to be traded at $132.98 in 30 days

Edwards Lifesciences Valuation Over Time

Enterprise Value

Edwards Lifesciences Company Summary

Edwards Lifesciences competes with Express Scripts, AmerisourceBergen, Baxter International, and BECTON DICKINSON. Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California. Edwards Lifesciences operates under Medical Devices classification in USA and traded on New York Stock Exchange. It employs 12200 people.

Edwards Lifesciences Operating Margin vs Revenue

Edwards Lifesciences Corporation is rated # 2 in operating margin category among related companies. It is rated below average in revenue category among related companies totaling about  115,436,242  of Revenue per Operating Margin.

Edwards Lifesciences Systematic Risk

The output start index for this execution was twenty with a total number of output elements of nineteen. The Beta measures systematic risk based on how returns on Edwards Lifesciences correlated with the market. If Beta is less than 0 Edwards Lifesciences generally moves in the opposite direction as compared to the market. If Edwards Lifesciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Edwards Lifesciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Edwards Lifesciences is generally in the same direction as the market. If Beta > 1 Edwards Lifesciences moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

Distress Rating

Edwards Lifesciences Financial Distress Probability
< 2% 

Chance of Financial Distress

Edwards Lifesciences Corporation has less than 2 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

Edwards Lifesciences Thematic Clasifications

Active Themes That Utilize Edwards Lifesciences
Obamacare Repeal IdeaObamacare RepealView
Medical Equipment IdeaMedical EquipmentView
Healthcare IdeaHealthcareView


Edwards Lifesciences Growth Changes

EPS Diluted Growth

EPS Growth

NCFO Growth


Compare Edwards Lifesciences To Peers

Opportunity Range

April 23, 2018 Opportunity Range
Additionally see Investing Opportunities. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.